For this reason, we hypothesized that in the AIO KRK-0104 trial primary tumor location in the left colon might have a favorable prognostic effect in patients with KRAS wild-type tumors, but not in patients with KRAS mutant tumors when receiving cetuximab-based first-line therapy. This evidence concerns the gene KRAS and neoplasm.